zileuton

FDA Drug Profile — ZYFLO, Zileuton

zileuton is listed in the FDA National Drug Code directory with 3 NDC codes, marketed under brand names including ZYFLO, Zileuton. Available dosage forms: tablet, tablet, multilayer, extended release.

Drug details

Generic Name
zileuton
Brand Names
ZYFLO, Zileuton
Application Number
NDA020471
Sponsor
Chiesi USA, Inc.
NDC Codes
3
Dosage Forms
TABLET, TABLET, MULTILAYER, EXTENDED RELEASE
Routes
ORAL
Active Ingredients
ZILEUTON

Indications and Usage

INDICATIONS AND USAGE ZYFLO is indicated for the prophylaxis and chronic treatment of asthma in adults and children 12 years of age and older.

Warnings

WARNINGS ZYFLO is not indicated for use in the reversal of bronchospasm in acute asthma attacks, including status asthmaticus. Therapy with ZYFLO can be continued during acute exacerbations of asthma. Co-administration of ZYFLO and theophylline results in, on average, an approximate doubling of serum theophylline concentrations. Theophylline dosage in these patients should be reduced and serum theophylline concentrations monitored closely (see PRECAUTIONS, Drug Interactions ). Co-administration of ZYFLO and warfarin results in a clinically significant increase in prothrombin time (PT). Patients on oral warfarin therapy and ZYFLO should have their prothrombin times monitored closely and anticoagulant dose adjusted accordingly (see PRECAUTIONS, Drug Interactions ). Co-administration of ZYFLO and propranolol results in doubling of propranolol AUC and consequent increased beta-blocker activity. Patients on ZYFLO and propranolol should be closely monitored and the dose of the propranolol reduced as necessary (see PRECAUTIONS, Drug Interactions ).

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.